Drugs / Omega-3 fatty acids
Omega-3 fatty acids
also known as
Omega-3 · fish oil · Omega-3 poly-unsaturated fatty acids · O3FA · Omacor · Omega-3 PUFAs · Polyunsaturated Fatty Acids · n-3 fatty acids · +27 more
targets RORA
Trials 82 · started per year
today
1
1
1
1
1
3
7
2
4
2
3
2
1
3
3
6
4
1
5
2
2
5
6
1
3
2
2
6
2
1986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02278965 | Jan 2015 → Apr 2017 | breast carcinoma in situ | Katherine D. Crew | Completed | No outcome recorded |
| Phase 1 | NCT01548157 | Mar 2012 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT01341925 | Sep 2011 → Sep 2014 | depressive disorder | L. Eugene Arnold | Completed | No outcome recorded |
| Phase 1 | NCT01507753 | Sep 2011 → Sep 2014 | bipolar disorder | L. Eugene Arnold | Completed | No outcome recorded |
| Phase 1 | NCT00399282 | Oct 2006 → Apr 2007 | rheumatoid arthritis | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07162688 | May 2025 → Mar 2028 expected | acute graft versus host disease | Fujian Medical University | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07067515 | Jan 2024 → Aug 2025 overdue | hyperpigmentation of the skin | Suez Canal University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03784963 | Jan 2019 → Jul 2020 | heart failure | University of Chicago | Terminated | No outcome recorded |
| Phase 1/2 | NCT02133664 | Jun 2014 → May 2016 | multiple sclerosis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/2 | NCT00421161 | Jan → Mar 2007 | dermatitis | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT05181189 | Aug 2026 → Mar 2028 expected | dementia | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07657468 | Jun → Oct 2026 expected | — | National University of La Rioja | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07050524 | Sep 2025 → Sep 2026 expected | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05774665 | Jan 2025 → Mar 2027 expected | obesity disorder | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05573672 | Aug 2022 → Nov 2023 | generalized anxiety disorder | The Canadian College of Naturopathic Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04518319 | Oct 2020 → Nov 2024 | schizophrenia | Shanghai Mental Health Center | Suspended | No outcome recorded |
| Phase 2 | NCT03313076 | Jul 2018 → Jul 2020 | — | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT03345550 | Sep 2017 → Jul 2021 | traumatic brain injury | University of Michigan | Terminated | No outcome recorded |
| Phase 2 | NCT02899741 | Aug 2016 → Nov 2018 | epilepsy | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01953705 | May 2014 → Dec 2020 | Alzheimer disease, subjective cognitive decline, vascular dementia | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 2 | NCT00289484 | Feb 2006 → ? | major depressive disorder | The University of New South Wales | Unknown | No outcome recorded |
| Phase 2 | NCT00962598 | Jan 2006 → Jun 2013 | major depressive disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00312897 | Dec 2005 → Jun 2013 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00238758 | Oct 2005 → ? | dysthymic disorder, major depressive disorder | The University of New South Wales | Unknown | No outcome recorded |
| Phase 2 | NCT00854737 | Jul 2004 → Aug 2007 | bipolar disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00402389 | Jun 2004 → Jan 2006 | postpartum depression | University of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT00010868 | Jul 2000 → Jul 2004 | bipolar disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00001146 | Oct 1999 → Aug 2002 | bipolar disorder, depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00004448 | Nov 1997 → Aug 2007 | IgA glomerulonephritis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00000461 | Dec 1986 → Nov 1992 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT05214495 | Feb → Sep 2022 | mucositis | Basma Morsy | Completed | No outcome recorded |
| Phase 2/3 | NCT04553705 | Sep → Nov 2020 | COVID-19, immunodeficiency disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT04292314 | Nov 2019 → Dec 2020 | beta-thalassemia major, disorder of defective peroxisome oxidative status, disorder of iron metabolism and transport | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT04301336 | Nov 2019 → Nov 2020 | sickle cell disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT03911843 | Jan 2017 → Dec 2018 | type 1 diabetes mellitus | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
| Phase 2/3 | NCT03627312 | Mar 2011 → Jul 2013 | disruptive behavior disorder | Singapore Prison Service | Completed | No outcome recorded |
| Phase 2/3 | NCT00511810 | Aug 2007 → Mar 2011 | major depressive disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 2/3 | NCT00360906 | Dec 2004 → Jul 2008 | relapsing-remitting multiple sclerosis | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00380926 | Apr → Nov 2004 | allergic asthma | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT02871440 | Sep 2016 → Sep 2017 | dry eye syndrome | The University of New South Wales | Completed | No outcome recorded |
| Phase 3 | NCT02128763 | Nov 2014 → Sep 2017 | dry eye syndrome | University of Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT01883817 | Sep 2013 → Mar 2017 | attention deficit-hyperactivity disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT02041520 | Jan 2013 → May 2014 | HIV infectious disease | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 3 | NCT01735279 | Jan → Dec 2013 | nicotine dependence | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT01686568 | Dec 2012 → Oct 2014 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00970489 | Aug 2010 → May 2012 | atrial fibrillation | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00729430 | Aug 2008 → Oct 2013 | myocardial infarction, sudden cardiac arrest | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00597220 | Jan 2008 → Jul 2011 | atrial fibrillation | Fundacion GESICA | Unknown | No outcome recorded |
| Phase 3 | NCT00422266 | Dec 2006 → Mar 2007 | hyperlipidemia | Centre for Chronic Disease Control, India | Completed | No outcome recorded |
| Phase 3 | NCT00067301 | Sep 2003 → Apr 2007 | major depressive disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 3 | NCT00069784 | Aug 2003 → Dec 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00392717 | Feb 1998 → Mar 2002 | hyperlipidemia, obesity disorder | The University of Western Australia | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT06254118 | Jan 2020 → Jan 2022 | chronic periodontitis | Hadir F. El-Dessouky | Completed | No outcome recorded |
| Phase 4 | NCT03911414 | Jun 2019 → Dec 2024 | mood disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03757585 | May 2019 → May 2024 | autism, non-verbal learning disability | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03686059 | Jul 2018 → Nov 2019 | eye adnexa disorder | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT03355638 | Jan → Jul 2016 | macular retinal edema | University of Brescia | Completed | No outcome recorded |
| Phase 4 | NCT01910948 | Jun → Dec 2013 | gastric cancer | Jian Suo | Unknown | No outcome recorded |
| Phase 4 | NCT00758927 | Jul 2009 → Apr 2010 | hyperlipoproteinemia, hypertriglyceridemia, type 2 diabetes mellitus | Inje University | Unknown | No outcome recorded |
| Phase 4 | NCT00634075 | Mar 2008 → Aug 2009 | infectious disease with sepsis | Li Shin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00141232 | Nov 2004 → Jul 2006 | type 2 diabetes mellitus | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00396643 | May 2004 → Jun 2007 | schizophrenia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00142220 | Jan 2004 → ? | infectious disease with sepsis | University Medicine Greifswald | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT06478290 | Oct 2025 → Jul 2026 overdue | — | University of Manitoba | Not yet recruiting | No outcome recorded |
| — | NCT07371416 | Oct 2025 → Dec 2026 expected | dental pulp necrosis | Mansoura University | Active not recruiting | No outcome recorded |
| — | NCT07036952 | Apr → Oct 2025 overdue | polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Enrolling by invitation | No outcome recorded |
| — | NCT06358963 | Feb → Apr 2024 | periodontal disorder | Amirhossein Farahmand | Unknown | No outcome recorded |
| — | NCT07138131 | Oct 2023 → Sep 2024 | cardiac rhythm disease | Benha University | Completed | No outcome recorded |
| — | NCT06463535 | Jun 2023 → Apr 2024 | periodontitis, type 2 diabetes mellitus | British University In Egypt | Completed | No outcome recorded |
| — | NCT05389046 | Aug 2022 → Dec 2024 | — | Peking University | Unknown | No outcome recorded |
| — | NCT07363551 | Jun 2021 → May 2026 overdue | attention deficit-hyperactivity disorder | China Medical University Hospital | Recruiting | No outcome recorded |
| — | NCT03708887 | Oct 2020 → Jan 2022 | hyperglycemia, hyperlipidemia | Zhejiang University | Completed | No outcome recorded |
| — | NCT04411615 | Jul → Aug 2020 | dry eye syndrome | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT04161989 | May 2020 → Jun 2022 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| — | NCT04389931 | Mar → Sep 2016 | periodontitis | Universidad Nacional Andres Bello | Completed | No outcome recorded |
| — | NCT02691533 | Feb 2016 → Dec 2017 | chronic liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02942602 | Apr 2014 → May 2016 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| — | NCT01515917 | Nov 2013 → Jul 2016 | substance abuse, substance dependence, traumatic brain injury | Deborah Yurgelun-Todd | Withdrawn | No outcome recorded |
| — | NCT01786239 | May 2013 → Sep 2015 | bipolar disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder | Delbert Robinson | Completed | No outcome recorded |
| — | NCT01502813 | Feb 2012 → Oct 2018 | — | Deborah Yurgelun-Todd | Completed | No outcome recorded |
| — | NCT00547716 | Jun 2009 → Aug 2012 | hepatitis C virus infection | University of Missouri, Kansas City | Withdrawn | No outcome recorded |
| — | NCT01315327 | May 2003 → Feb 2006 | Tourette syndrome | NYU Langone Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 46 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 28 trials | ||||||
| Phase 2 | NCT02569307 Comparator | Oct 2015 → Dec 2018 | psychotic disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT02696577 Comparator | Mar 2015 → Jan 2016 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02106468 Comparator | May 2013 → Jun 2014 | lichen planus, oral | October 6 University | Completed | No outcome recorded |
| Phase 2 | NCT01694667 Comparator | Sep → Dec 2012 | autism spectrum disorder | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02373579 Comparator | Jun 2012 → Oct 2014 | acute lymphoblastic leukemia | Nancy Samir Elbarbary | Completed | No outcome recorded |
| Phase 2 | NCT01831453 Comparator | Apr 2012 → Apr 2013 | aphthous stomatitis | October 6 University | Unknown | No outcome recorded |
| Phase 2 | NCT01399827 Comparator | Feb 2012 → Nov 2017 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00917501 Comparator | Jun 2009 → Jul 2013 | manic bipolar affective disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07399743 Comparator | Feb → Jun 2026 overdue | osteoarthritis, knee | Badr University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02757872 Comparator | Apr 2016 → Mar 2022 | hypertensive disorder, kidney disorder | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02152930 Comparator | Dec 2014 → Feb 2016 | intermittent vascular claudication | Medical Center Alkmaar | Terminated | No outcome recorded |
| Phase 3 | NCT02192580 Comparator | Jul 2014 → Jul 2015 | acute pyelonephritis | Shahid Beheshti University | Unknown | No outcome recorded |
| Phase 3 | NCT01813006 Comparator | Mar 2013 → Dec 2016 | familial hypercholesterolemia | Nordland Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02178410 Comparator | Oct 2012 → Oct 2026 expected | cardiovascular disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01723345 Comparator | Feb 2012 → Mar 2013 | coronary atherosclerosis | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01521845 Comparator | Jan → May 2012 | coronary atherosclerosis | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01169259 Comparator | Jul 2010 → Nov 2018 overdue | cancer, cardiovascular disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00935766 Comparator | Sep 2009 → Mar 2012 | diabetes mellitus, heart disorder, hypertensive disorder | Denver Health and Hospital Authority | Terminated | No outcome recorded |
| Phase 3 | NCT01235130 Comparator | Mar 2009 → Dec 2012 | atrial fibrillation | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT00211562 Comparator | Oct 2005 → Jan 2006 | schizophrenia | Augusta University | Terminated | No outcome recorded |
| Phase 3 | NCT00116857 Comparator | Feb 2005 → Jun 2009 | depressive disorder, intermediate coronary syndrome, myocardial infarction | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05365438 Comparator | Oct 2022 → Dec 2026 expected | atherosclerosis, hyperlipidemia, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02597439 Comparator | Sep 2016 → Feb 2023 | — | Rene Kahn | Completed | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT02642159 Comparator | Mar 2016 → Mar 2017 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02206256 Comparator | Nov 2014 → Nov 2016 | morbid obesity | Medical Center Alkmaar | Completed | No outcome recorded |
| Phase 4 | NCT01744067 Comparator | Nov 2013 → Dec 2015 | disease related to solid organ transplantation | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01733147 Comparator | Nov 2012 → Sep 2018 | Barrett esophagus, obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01396486 Comparator | Feb 2012 → Apr 2019 | bipolar disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT05980026 Comparator | Jan → Dec 2022 | type 1 diabetes mellitus | Ain Shams University | Completed | No outcome recorded |
| — | NCT04573946 Comparator | Jul 2019 → Jul 2023 overdue | disease of bone structure | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| — | NCT02800252 Comparator | Jun 2016 → Dec 2018 | chronic periodontitis, type 2 diabetes mellitus | São Paulo State University | Unknown | No outcome recorded |
| — | NCT03388450 Comparator | Jan 2015 → Oct 2017 | infectious disease with sepsis | Menoufia University | Completed | No outcome recorded |
| — | NCT01841944 Comparator | Nov 2012 → Jun 2020 | atrial fibrillation, coronary artery disorder, heart failure, myocardial infarction | Oslo University Hospital | Completed | No outcome recorded |
| — | NCT01632761 Comparator | Nov 2012 → Dec 2025 overdue | anemia | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| — | NCT01785004 Comparator | Jul 2012 → Jul 2022 | obesity disorder | Brigham and Women's Hospital | Unknown | No outcome recorded |
| — | NCT01653678 Comparator | Nov 2011 → Nov 2025 overdue | hypertensive disorder | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| — | NCT01669915 Comparator | Sep 2011 → Jun 2016 | cognitive disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01684722 Comparator | Jul 2010 → Nov 2019 | type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| — | NCT01782352 Comparator | Jul 2010 → Dec 2019 | age-related macular degeneration | Brigham and Women's Hospital | Unknown | No outcome recorded |
| — | NCT01696435 Comparator | Jul 2010 → Dec 2021 | depressive disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT01880463 Comparator | Jul 2010 → Dec 2020 | dry eye syndrome | Brigham and Women's Hospital | Unknown | No outcome recorded |
| — | NCT01704664 Comparator | Mar 2007 → Jul 2021 | gastric cancer | Medical University of Bialystok | Unknown | No outcome recorded |
| — | NCT00467818 Comparator | Jan 2007 → Dec 2010 | autism | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-10-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New product for Japanese women Nature Made Fish Oil Pearl Small Pearl-shaped Capsules Concentrated With Essential Nutritional Balance of Fish Oil otsuka.co.jp ↗ |
Evidence & citations 40 cited values
Every value below carries the sentence it was read from. 141 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omega-3 fatty acids | “Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of...” NCT05573672 ↗63“OBJECTIVES: To assess the effects of n-3 polyunsaturated fatty acids (also known as omega-3 fatty acids) versus a comparator (e.g. placebo, antidepressant treatment, standard...” PMID 34817851 ↗ Nov 2021 “The purpose of this study is to determine whether simultaneous supplementation with omega-3 fatty acids and vitamin E is effective in the treatment of patients with rheumatoid...” NCT00399282 ↗ “Pre-treatment with omega-3 fatty acids has similar effects on liver volume, but a prospective comparison of both treatments has not been performed yet.” NCT02206256 ↗ “Participants assigned to the experimental group will receive Omega-3 fatty acids supplementation as part of their treatment regimen.” NCT07050524 ↗ “Many clinicians recommend the use of supplements of n-3 fatty acids (often called omega-3 fatty acids) to relieve symptoms.” PMID 29652551 ↗ Apr 2018 “mild traumatic brain injury (omega-3 fatty acids, education only)” NCT02670161 ↗ “Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)” NCT00511810 ↗ “Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year” NCT03708887 ↗ “dietary supplements such as omega-3 fatty acids (Ω3).” NCT01341925 ↗ “omega-3 fatty acids (4g po daily for 4 months)” NCT00854737 ↗ “Omega-3 Fatty Acids - 4 grams per day” NCT00547716 ↗ “omega-3 fatty acids” NCT06254118 ↗ |
| Known as | Azyr Mega | “Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).” NCT03355638 ↗ |
| Known as | DHA Omega-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01883817 ↗ |
| Known as | fatty acids, omega-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000461 ↗ |
| Known as | fish oil | “Native populations consuming high amounts of fish suffer less from allergic diseases. The purpose of this study is to determine whether polyunsaturated fatty acids (fish oil)...” NCT00380926 ↗14“In this 14 month double-blind, randomized controlled trial, 415 patients with type 2 diabetes (T2D) were randomly assigned to receive high-dose (3.0 g/day) or low-dose (1.5...” PMID 41559698 ↗ Jan 2026 “The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional...” NCT00511810 ↗ “participants will be randomly allocated to receive either Omega-3 (fish oil) or placebo (paraffin oil)for 4 weeks.” NCT00289484 ↗ “Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.” NCT03345550 ↗ “Participants will be randomly allocated to receive Omega-3 (fish oil) or placebo (paraffin oil) for 6 weeks.” NCT00238758 ↗ “Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day.” NCT01632761 ↗ “Drug: Omega-3 fatty acids (fish oil)” NCT01684722 ↗ “Omega-3 fatty acids (fish oil)” NCT01880463 ↗ “Omega-3 fatty acids (fish oil)” NCT01782352 ↗ “Omega-3 fatty acids (fish oil)” NCT02178410 ↗ “Omega-3 fatty acids (fish oil)” NCT01653678 ↗ “Omega-3 fatty acids (fish oil)” NCT04573946 ↗ “omega-3 fatty acids (fish oil)” NCT01785004 ↗ “omega-3 fatty acids (fish oil)” NCT01669915 ↗ |
| Known as | Fish Oil Supplements | “Omega-3 Fatty Acids (Fish Oil Supplements)” NCT00729430 ↗ |
| Known as | Fish oils | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00392717 ↗ |
| Known as | Limitless Omega | “Omega-3 cap 2000 mg BID (Limitless Omega) + PT” NCT07399743 ↗ |
| Known as | marine n-3 polyunsaturated fatty acids | “either marine n-3 polyunsaturated fatty acids (n-3 PUFA) or soybean oil placebo” PMID 30934894 ↗ Mar 2019 |
| Known as | n-3 fatty acids | “Omega-3 or "n-3" polyunsaturated fatty acids (n-3 fatty acids) represent a novel approach to the prevention and treatment of AF.” NCT01235130 ↗1“Many clinicians recommend the use of supplements of n-3 fatty acids (often called omega-3 fatty acids) to relieve symptoms.” PMID 29652551 ↗ Apr 2018 |
| Known as | n-3 polyunsaturated fatty acids | “One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also known as omega-3 oils, naturally found in fatty fish, some other seafood, and some nuts and seeds.” PMID 34817851 ↗ Nov 2021 |
| Known as | n-3 PUFA | “Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplements have demonstrated an effect on cardiovascular endpoints in some clinical trials.” PMID 36999528 ↗ Mar 20231“either marine n-3 polyunsaturated fatty acids (n-3 PUFA) or soybean oil placebo” PMID 30934894 ↗ Mar 2019 |
| Known as | n-3FA | “n-3 polyunsaturated fatty acid (n-3FA) supplements” PMID 23564916 ↗ Apr 2013 |
| Known as | n-3PUFAs | “One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also known as omega-3 oils, naturally found in fatty fish, some other seafood, and some nuts and seeds.” PMID 34817851 ↗ Nov 2021 |
| Known as | O3FA | “This randomized, placebo-controlled, double-blind trial evaluated the role of prednisone and omega 3 fatty acids (O3FA) in patients with IgA nephropathy.” PMID 17699247 ↗ Apr 20063“6-month treatment with omega-3 fatty acid (O-3FA) 4 g/day attenuated cardiac remodeling accompanied by reduction in inflammation.” PMID 31948661 ↗ Dec 2019 “Clinical observations have suggested therapeutic effects for ω-3 fatty acids (O3FA) in Tourette's disorder (TD).” PMID 22585765 ↗ May 2012 “omega-3 fatty acids (O3FA), given as fish oil capsules” PMID 22926607 ↗ Oct 2012 |
| Known as | Omacor | “The Effect of Omega-3 Fatty Acids (Omacor@) on the Response Rate to Antiviral Therapy in Patients With Chronic Hepatitis C Infection” NCT00547716 ↗3“Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids” NCT02757872 ↗ “Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day.” NCT01632761 ↗ “Omega-3, Omacor” NCT02899741 ↗ |
| Known as | Omega 3 fatty acids and plant sterol enriched drink | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422266 ↗ |
| Known as | Omega 3 plus | “received omega 3 (Omega 3 plus, SEDICO, Egypt); once daily from 28-30 weeks till delivery.” NCT04161989 ↗ |
| Known as | Omega 3 PUFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01953705 ↗ |
| Known as | Omega-3 | “Most of studies on omega-3 fatty acids (omega-3) supplementation in patients with rheumatoid arthritis (RA) have clearly shown potentially beneficial changes in cytokine and...” NCT00399282 ↗45“A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers” NCT01548157 ↗ “Impact of the Adjunctive Use of Omega-3 in Periodontitis Patients With Diabetes on Local and Systemic Chemerin Levels: A Randomized Clinical Trial.” PMID 40771657 ↗ Jul 2025 “Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication” NCT06358963 ↗ “participants will be randomly allocated to receive either Omega-3 (fish oil) or placebo (paraffin oil)for 4 weeks.” NCT00289484 ↗ “Omega-3 2000mg (920mg as EPA ethyl ester, 760mg as DHA ethyl ester) once daily” NCT05365438 ↗ “Omega-3 supplementation 1000mg contains” NCT04553705 ↗ “Omega 3 (n-3 PUFA)” NCT00597220 ↗ |
| Known as | Omega-3 acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00758927 ↗ |
| Known as | Omega-3 Lipid Emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162688 ↗ |
| Known as | omega-3 oils | “One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also known as omega-3 oils, naturally found in fatty fish, some other seafood, and some nuts and seeds.” PMID 34817851 ↗ Nov 2021 |
| Known as | Omega-3 poly-unsaturated fatty acids | “6.Omega-3 poly-unsaturated fatty acids (1000mg) was given as an adjunctive treatment daily for 6 months to group 2, starting 2 weeks after phase 1 therapy.” NCT06463535 ↗8“Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation” NCT07067515 ↗ |
| Known as | omega-3 polyunsaturated fatty acids (PUFAs) | “Omega -3 polyunsaturated fatty acids (PUFAs) have antiplatelet effect.” NCT01521845 ↗ |
| Known as | Omega-3 PUFAs | “Group I was given a daily oral dose of 2 g of Omega-3 PUFAs before and after one weekly intragingival injections of 1–2 g of omega-3.” PMID 42046081 ↗ Apr 20263“Each capsule contains 1 gram of Omega3(PUFAs) as an additional food supplement” NCT07067515 ↗ “1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva” NCT07067515 ↗ |
| Known as | Omega-3 Supplementation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01507753 ↗ |
| Known as | OmegaBrite | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001146 ↗ |
| Known as | Omegavan | “Group A subjects will receive ω3 PUFA (Polyunsaturated Fatty Acids) (10% Omegavan 100 ml).” NCT02691533 ↗ |
| Known as | Omegaven | “A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags.” NCT01704664 ↗ |
| Known as | Pikasol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01841944 ↗ |
| Known as | Polyunsaturated Fatty Acids | “We investigated the anti-inflammatory potential of polyunsaturated fatty acids (PUFA) in allergic asthma.” NCT00380926 ↗ |
| Known as | PUFA | “omega-3 polyunsaturated fatty acids (PUFA)” NCT00069784 ↗ |
| Known as | Triomar | “concentrated omega-3 fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard immunomodulatory therapy defined as interferon-beta 1a (Rebif™).” NCT00360906 ↗ |
| Known as | ω-3 PUFA | “Three-year treatment with 1.65 g of ω-3 PUFA (975 mg of EPA and 650 mg of DHA) vs a soybean oil placebo matched for taste, smell, and appearance” PMID 39088212 ↗ Aug 2024 |
| Known as | ω3-fatty acids | “A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags.” NCT01704664 ↗ |
| Action | Restore | “supplementation with these fatty acids can restore the levels of omega-3 and could decrease nicotine dependence” NCT01735279 ↗ |
| Modality | Other / unclassified | “adding vitamins and fats (nutritional supplements) to a diet” NCT00211562 ↗ |
| Route | Oral | “either oral omega-3 fatty acid (Triomar™) or placebo” NCT00360906 ↗ |
| Target | RORA | “Notably, n-3 PUFAs target RORα to regulate circadian clock oscillations and facilitate BMAL1 nuclear translocation.” PMID 40347940 ↗ May 2025 |